Brussels, 28/06/2005 (Agence Europe) - In a 27 June press release, the European Agency for the Evaluation of Medicinal Products (EMEA) has announced the end of its examination of the Cox-2 inhibitors, which it began on 22 October 2004, a few weeks after the withdrawal of Merc&Co of its anti-inflammatory Vioxx. At the end of another medicines for human use committee meeting, EMEA confirms the suspension of another non-steroid anti-inflamatory belonging to this family: Bextra (valdecoxib), which the Pfizer laboratory withdrew from the European market in April 2005. A new authorisation procedure will now be necessary for this product, which has potentially fatal skin reactions: Stevens-Johnson syndrome or Erythrodermic or generalized pustular psoriasis. Due to significant cardiovascular dangers in other substances in this family (celecoxib, etoricoxib, lumiracoxib and parecoxib), EMEA is also requesting that the list of counter-indications and warnings on these products is completed.